Advertisement

Molecular Determinants of Natriuretic Peptide Clearance Receptor Function

  • John A. Lewicki
  • Andrew A. Protter
Part of the Contemporary Endocrinology book series (COE, volume 5)

Abstract

The natriuretic peptides, atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and C-type natriuretic peptide (CNP), elicit their hemodynamic, renal, and neuroendocrine actions via a series of specific receptors on target tissues. To date, three natriuretic peptide receptors have been elucidated and characterized in detail. Two of these receptors are membrane-associated guanylyl cyclases, termed GC-A and GC-B. These receptors, which are reviewed in detail Chapters 3,4, and 6–8, mediate many of the direct biological actions of these peptides. The natriuretic peptide clearance (NP-C) receptor comprises the third member of this receptor family. As its name implies, the NP-C receptor is a unique protein that plays a central role in mediating the metabolic clearance of the natriuretic peptides from the circulation. The NP-C receptor thus serves to regulate plasma concentrations of the natriuretic peptides. Recent data also suggest that this receptor may be responsible for some direct actions of the natriuretic peptides, although the physiological significance of these events is unclear.

Keywords

Natriuretic Peptide Atrial Natriuretic Peptide Atrial Natriuretic Factor Natriuretic Peptide Receptor Clearance Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schenk DB, Phelps MN, Porter JG, Fuller F, Cordell B, Lewicki JA. Purification and subunit composition of atrial natriuretic peptide receptor. Proc Natl Acad Sci USA 1987;84:1521–1525.PubMedCrossRefGoogle Scholar
  2. 2.
    Fuller F, Porter JG, Arfsten AE, Miller J, Schilling JW, Scarborough RM, Lewicki JA, Schenk DB. Atrial natriuretic peptide clearance receptor. Complete sequence and functional expression of cDNA clones. J Biol Chem 1988;263:9395–9401.PubMedGoogle Scholar
  3. 3.
    Porter JG, Arfsten A, Fuller F, Miller JA, Gregory LC, Lewicki JA. Isolation and functional expression of the human atrial natriuretic peptide clearance receptor cDNA. Biochem Biophys Res Commun 1990;171:796–803.PubMedCrossRefGoogle Scholar
  4. 4.
    Lowe DG, Camerato TR, Goeddel DV. cDNA sequence of the human atrial natriuretic peptide clearance receptor. Nucleic Acids Res 1990;18:3412.PubMedCrossRefGoogle Scholar
  5. 5.
    Engel AM, Schoenfeld JR, Lowe DG. A single residue determines the distinct pharmacology of rat and human natriuretic peptide receptor-C. J Biol Chem 1994;269:17,005–17,008.Google Scholar
  6. 6.
    Saheki T, Mizuno T, Iwata T, Saito Y, Nagasawa T, Mizuno KU, Ito F, Ito T, Hagiwara H, Hirose S. Structure of the bovine atrial natriuretic peptide receptor (type C) gene. J Biol Chem 1991;266:11,122–11,125.Google Scholar
  7. 7.
    Porter JG, Scarborough RM, Wang Y, Schenk, D, McEnroe GA, Kang LL, Lewicki JA. Recombinant expression of a secreted form of the atrial natriuretic peptide clearance receptor. J Biol Chem 1989;264:14,179–14,184.Google Scholar
  8. 8.
    Bennett BD, Bennett GL, Vitangcol RV, Jewett JR, Burnier J, Henzel W, Lowe DG. Extracellular domain-IgG fusion proteins for three human natriuretic peptide receptors. Hormone pharmacology and application to solid phase screening of synthetic peptide antisera. J Biol Chem 1991;266:23,060–23,067.Google Scholar
  9. 9.
    Itakura M, Iwashina M, Mizuno T, Ito T, Hagiwara H, Hirose S. Mutational analysis of disulfide bridges in the type C atrial natriuretic peptide receptor. J Biol Chem 1994;269:8314–8318.PubMedGoogle Scholar
  10. 10.
    Stults JT, O’Connell KL, Garcia C, Wong S, Engel AM, Garbers DL, Lowe DG. The disulfide linkages and glycosylation sites of the human natriuretic peptide receptor-C homodimer. Biochemistry 1994;33:11,372–11,381.CrossRefGoogle Scholar
  11. 11.
    Cohen D, Koh GY, Nikonova LN, Porter JG, Maack T. Molecular determinants of the clearance function of type C receptors of natriuretic peptides. J Biol Chem 1996;271:9863–9869.PubMedCrossRefGoogle Scholar
  12. 12.
    Iwashina M, Mizuno T, Hirose S, Ito T, Hagiwara H. Hisl45-Trpl46 residues and the disulfide-linked loops in atrial natriuretic peptide receptor are critical for the ligand-binding activity. J Biochem 1994:115:563–567.PubMedGoogle Scholar
  13. 13.
    Engel AM, Lowe DG. Characterization of the hormone binding site of natriuretic peptide receptor-C. FEBS Lett 1995;360:169–172.PubMedCrossRefGoogle Scholar
  14. 14.
    Mizuno T, Iwashina M, Itakura M, Hagiwara H, Hirose S. A variant form of the type C atrial natriuretic peptide receptor generated by alternative RNA splicing. J Biol Chem 1993;268:5162–5167.PubMedGoogle Scholar
  15. 15.
    Maack T, Suzuki M, Almeida FA, Nussenzveig D, Scarborough RM, McEnroe GA, Lewicki JA. Physiological role of silent receptors of atrial natriuretic factor. Science 1987;238:675–678.PubMedCrossRefGoogle Scholar
  16. 16.
    Martin ER, Lewicki JA, Scarborough RM, Ballermann BJ. Expression and regulation of ANP receptor subtypes in rat renal glomeruli and papillae. Am J Physiol 1989;257:F649–657.PubMedGoogle Scholar
  17. 17.
    Kollenda MC, Vollmar AM, McEnroe GA, Gerbes AL. Dehydration increases the density of C receptors for ANF on rat glomerular membranes. Am J Physiol 1990;258:R1084–1088.PubMedGoogle Scholar
  18. 18.
    Koh GY, Nussenzveig DR, Okolicany J, Price DA, Maack T. Dynamics of atrial natriuretic factor-guanylate cyclase receptors and receptor-ligand complexes in cultured glomerular mesangial and renomedullary interstitial cells. J Biol Chem 1992;267:11,987–11,994.Google Scholar
  19. 19.
    Chansel D, Pham P, Nivez MP, Ardaillou R. Characterization of atrial natriuretic factor receptors in human glomerular epithelial and mesangial cells. Am J Physiol 1990;259:F619–627.PubMedGoogle Scholar
  20. 20.
    Yamamoto T, Feng L, Mizuno T, Hirose S, Kawasaki K, Yaoita E, Kihara I, Wilson CB. Expression of mRNA for natriuretic peptide receptor subtypes in bovine kidney. Am J Physiol 1994;267:F318–324.PubMedGoogle Scholar
  21. 21.
    Bea ML, Dussaule JC, Bens M, Ardaillou R. Characterization of ANF receptors in cultured renal cortical vascular smooth muscle cells. Am J Physiol 1991;260:C424–432.PubMedGoogle Scholar
  22. 22.
    Brown J, Salas SP, Singleton A, Polak JM, Dollery CT. Autoradiographic localization of atrial natriuretic peptide receptor subtypes in rat kidney. Am J Physiol 1990;259:F26–39.PubMedGoogle Scholar
  23. 23.
    Wilcox JN, Augustine A, Goeddel DV, Lowe DG. Differential regional expression of three natriuretic peptide receptor genes within primate tissues. Mol Cell Biol 1991;11:3454–3462.PubMedGoogle Scholar
  24. 24.
    Meloche S, Ong H, Cantin M, De Lean A. Affinity cross-linking of atrial natriuretic factor to its receptor in bovine adrenal zona glomerulosa. J Biol Chem 1986;261:1525–1528.PubMedGoogle Scholar
  25. 25.
    Heisler S, Morrier E. Bovine adrenal medullary cells contain functional atrial natriuretic peptide receptors. Biochem Biophys Res Commun 1988;150:781–787.PubMedCrossRefGoogle Scholar
  26. 26.
    Nunez DJ, Dickson MC, Brown MJ. Natriuretic peptide receptor mRNAs in the rat and human heart. J Clin Invest 1992;90:1966–1971.PubMedCrossRefGoogle Scholar
  27. 27.
    Brown LA, Nunez DJ, Wilkins MR. Differential regulation of natriuretic peptide receptor messenger RNAs during the development of cardiac hypertrophy in the rat. J Clin Invest 1993;92:2702–2712.PubMedCrossRefGoogle Scholar
  28. 28.
    Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 1995;25:227–234.PubMedGoogle Scholar
  29. 29.
    Li H, Oparil S, Meng QC, Elton TS, Chen YF. Selective downregulation of ANP-clearance-receptor gene expression in lung of rats adapted to hypoxia. Am J Physiol 1995;268:L328–335.PubMedGoogle Scholar
  30. 30.
    Schenk DB, Johnson LK, Schwartz K, Sista H, Scarborough RM, Lewicki JA. Distinct atrial natriuretic factor receptor sites on cultured bovine aortic smooth muscle and endothelial cells. Biochem Biophys Res Commun 1985;127:433–442.PubMedCrossRefGoogle Scholar
  31. 31.
    Leitman DC, Andresen JW, Catalano RM, Waldman SA, Tuan JJ, Murad F. Atrial natriuretic peptide binding, cross-linking, and stimulation of cyclic GMP accumulation and particulate guanylate cyclase activity in cultured cells. J Biol Chem 1988;263:3720–3728.PubMedGoogle Scholar
  32. 32.
    Pandey KN, Pavlou SN, Inagami T. Identification and characterization of three distinct atrial natriuretic factor receptors. Evidence for tissue-specific heterogeneity of receptor subtypes in vascular smooth muscle, kidney tubular epithelium, and Leydig tumor cells by ligand binding, photoaffinity labeling, and tryptic proteolysis. J Biol Chem 1988;263:13,406–13,413.Google Scholar
  33. 33.
    Scarborough RM, Schenk DB, McEnroe GA, Arfsten A, Kang LL, Schwartz K, Lewicki JA. Truncated atrial natriuretic peptide analogs. Comparison between receptor binding and stimulation of cyclic GMP accumulation in cultured vascular smooth muscle cells. J Biol Chem 1986;261:12,960–12,964.Google Scholar
  34. 34.
    Suga S, Nakao K, Hosoda K, Mukoyama M, Ogawa Y, Shirakami G, Arai H, Saito Y, Kambayashi Y, Inouye K, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 1992;130:229–239.PubMedCrossRefGoogle Scholar
  35. 35.
    Suga S, Nakao K, Kishimoto I, Hosoda K, Mukoyama M, Arai H, Shirakami G, Ogawa Y, Komatsu Y, Nakagawa O, et al. Phenotype-related alteration in expression of natriuretic peptide receptors in aortic smooth muscle cells. Circ Res 1992;71:34–39.PubMedGoogle Scholar
  36. 36.
    Perrella MA, Margulies KB, Wei CM, Aarhus LL, Heublein DM, Burnett J Jr. Pulmonary and urinary clearance of atrial natriuretic factor in acute congestive heart failure in dogs. J Clin Invest 1991;87:1649– 1655.PubMedCrossRefGoogle Scholar
  37. 37.
    Hollister AS, Rodeheffer RJ, White FJ, Potts JR, Imada T, Inagami T. Clearance of atrial natriuretic factor by lung, liver, and kidney in human subjects and the dog. J Clin Invest 1989;83:623–628.PubMedCrossRefGoogle Scholar
  38. 38.
    Masuda T, Shichiri M, Marumo F. Degradation of atrial natriuretic peptide in dogs. Acta Endocrinol 1989;120:170–174.PubMedGoogle Scholar
  39. 39.
    von Schroeder HP, Nishimura E, Mcintosh CH, Buchan AM, Wilson N, Ledsome JR. Autoradiographic localization of binding sites for atrial natriuretic factor. Can J Physiol Pharmacol 1985;63:1373–1377.CrossRefGoogle Scholar
  40. 40.
    Shimonaka M, Saheki T, Hagiwara H, Ishido M, Nogi A, Fujita T, Wakita K, Inada Y, Kondo J, Hirose S. Purification of atrial natriuretic peptide receptor from bovine lung. Evidence for a disulfide-linked subunit structure. J Biol Chem 1987;262:5510–5514.PubMedGoogle Scholar
  41. 41.
    Uchida K, Mizuno T, Shimonaka M, Sugiura N, Nara K, Ling N, Hagiwara H, Hirose S. Purification and properties of active atrial-natriuretic-peptide receptor (type C) from bovine lung. Biochem J 1989;263:671–678.PubMedGoogle Scholar
  42. 42.
    Klinger JR, Moalli R, Warburton RR, Wrenn DS, Hill NS. C-receptor ligand blocks pulmonary clearance of atrial natriuretic peptide in isolated rat lungs. Proc Soc Exp Biol Med 1992;201:154–158.PubMedGoogle Scholar
  43. 43.
    Souque A, Gros C, Schwartz JC. Binding of [125I]atrial natriuretic factor to mouse lung membranes in vivo: characterization and effects of peptidase inhibitors. J Pharmacol Exp Ther 1992;260:1373–1378.PubMedGoogle Scholar
  44. 44.
    Brandt RR, Redfield MM, Aarhus LL, Lewicki JA, Burnett J Jr. Clearance receptor-mediated control of atrial natriuretic factor in experimental congestive heart failure. Am J Physiol 1994;266:R936–943.PubMedGoogle Scholar
  45. 45.
    Lindberg BF, Bengtsson HI, Lundin S, Andersson KE. Degradation and inactivation of rat atrial natriuretic peptide 1–28 by neutral endopeptidase-24.11 in rat pulmonary membranes. Regul Pept 1992;42:85–96.PubMedCrossRefGoogle Scholar
  46. 46.
    Numan NA, Gillespie MN, Altiere RJ. Pulmonary clearance of atrial natriuretic peptides. Pulm Pharmacol 1990;3:25–28.PubMedCrossRefGoogle Scholar
  47. 47.
    Zhao L, Hughes JM, Winter RJ. Effects of natriuretic peptides and neutral endopeptidase 24.11 inhibition in isolated perfused rat lung. Am Rev Respir Dis 1992;146:1198–1201.PubMedGoogle Scholar
  48. 48.
    Chabrier PE, Roubert P, Lonchampt MO, Plas P, Braquet P. Regulation of atrial natriuretic factor receptors by angiotensin II in rat vascular smooth muscle cells. J Biol Chem 1988;263:13,199–13,202.Google Scholar
  49. 49.
    Cahill PA, Redmond EM, Keenan AK. Vascular atrial natriuretic factor receptor subtypes are not independently regulated by atrial peptides. J Biol Chem 1990;265:21,896–21,906.Google Scholar
  50. 50.
    Kato J, Lanier-Smith KL, Currie MG. Cyclic GMP down-regulates atrial natriuretic peptide receptors on cultured vascular endothelial cells. J Biol Chem 1991;266:14,681–14,685.Google Scholar
  51. 51.
    Zhang LM, Tao H, Newman WH. Regulation of atrial natriuretic peptide receptors in vascular smooth muscle cells: role of cGMP. Am J Physiol 1993;264:H1753–1759.PubMedGoogle Scholar
  52. 52.
    Paul RV, Wackym PS, Budisavljevic M, Everett E, Norris JS. Regulation of atrial natriuretic peptide clearance receptors in mesangial cells by growth factors. J Biol Chem 1993;268:18,205–18,212.Google Scholar
  53. 53.
    Paulding WR, and Sumners C. Protein kinase C modulates natriuretic peptide receptors in astroglial cultures from rat brain. Am J Physiol 1996;270:C740–747.PubMedGoogle Scholar
  54. 54.
    Kishimoto I, Yoshimasa T, Suga S, Ogawa Y, Komatsu Y, Nakagawa O, Itoh H, Nakao K. Natriuretic peptide clearance receptor is transcriptionally down-regulated by beta 2-adrenergic stimulation in vascular smooth muscle cells. J Biol Chem 1994;269:28,300–28,308.Google Scholar
  55. 55.
    Brandt RR, Heublein DM, Aarhus LL, Lewicki JA, Burnett J Jr. Role of natriuretic peptide clearance receptor in in vivo control of C-type natriuretic peptide. Am J Physiol 1995;269:H326–331.PubMedGoogle Scholar
  56. 56.
    Scarborough RM, McEnroe GA, Arfsten A, Kang LL, Schwartz K, Lewicki JA. D-amino acid-substituted atrial natriuretic peptide analogs reveal novel receptor recognition requirements. J Biol Chem 1988;263:16,818–16,822.Google Scholar
  57. 57.
    McEnroe GA, Scarborough RM, Gregory LC, Okolicany J, Porter G, Maack T, Lewicki JA. Synthesis and biological properties of specific ANP C-receptor ligands. In: Peptide Regulation of Cardiovascular Function. Takeda Science Foundation, 1991, pp. 65–77.Google Scholar
  58. 58.
    Almeida FA, Suzuki M, Scarborough RM, Lewicki JA, Maack T. Clearance function of type C receptors of atrial natriuretic factor in rats. Am J Physiol 1989;256:R469–475.PubMedGoogle Scholar
  59. 59.
    Abassi ZA, Tate J, Hunsberger S, Klein H, Trachewsky D, Keiser HR. Pharmacokinetics of ANF and urodilatin during cANF receptor blockade and neutral endopeptidase inhibition. Am J Physiol 1992;263:E870–876.PubMedGoogle Scholar
  60. 60.
    Chiu PJ, Tetzloff G, Romano MT, Foster CJ, Sybertz EJ. Influence of C-ANF receptor and neutral endopeptidase on pharmacokinetics of ANF in rats. Am J Physiol 1991;260:R208–216.PubMedGoogle Scholar
  61. 61.
    Castro R, Ervin MG, Leake RD, Ross MG, Fisher DA. Effect of a ring-deleted atrial natriuretic factor analogue on ovine fetal renal and cardiovascular function. Pediatr Res 1991;29:342–346.PubMedGoogle Scholar
  62. 62.
    Okolicany J, McEnroe GA, Gregory LC, Lewicki JA, Maack T. Effects of small C-ANF receptor ligands on plasma levels of atrial natriuretic factor, blood pressure, and renal function in the rat. Can J Physiol Pharmacol 1991;69:1561–1566.PubMedCrossRefGoogle Scholar
  63. 63.
    Kukkonen P, Vuolteenaho 0, Ruskoaho H. Basal and volume expansion-stimulated plasma atrial natriuretic peptide concentrations and hemodynamics in conscious rats: effects of SCH 39.370, an endopep-tidase inhibitor, and C-ANF-(4–23), a clearance receptor ligand. Endocrinology 1992;130:755–765.PubMedCrossRefGoogle Scholar
  64. 64.
    Seymour AA, Norman JA, Asaad MM, Fennell SA, Abboa-Offei B, Little DK, Kratunis VJ, Delaney NG, Hunt JT, Di Donato G. Possible regulation of atrial natriuretic factor by neutral endopeptidase 24.11 and clearance receptors. J Pharmacol Exp Ther 1991;256:1002–1009.PubMedGoogle Scholar
  65. 65.
    Okolicany J, McEnroe GA, Koh GY, Lewicki JA, Maack T. Clearance receptor and neutral endopep-tidase-mediated metabolism of atrial natriuretic factor. Am J Physiol 1992;263:F546–553.PubMedGoogle Scholar
  66. 66.
    Wegner M, Stasch JP, Hirthdietrich C, Dressel J, Voges KP, Kazda S. Interaction of a neutral endopeptidase inhibitor with an ANP-C receptor ligand in anesthetized dogs. Clin Exp Hypertension 1995;17:861–876.CrossRefGoogle Scholar
  67. 67.
    Koepke JP, Tyler LD, Trapani AJ, Bovy PR, Spear KL, Olins GM, Blaine EH. Interaction of non-guanylate cyclase-linked atriopeptin receptor ligand and endopeptidase inhibitor in conscious rats. J Pharmacol Exp Ther 1989;249:172–176.PubMedGoogle Scholar
  68. 68.
    Hashimoto Y, Nakao K, Hama N, Imura H, Mori S, Yamaguchi M, Yasuhara M, Hori R. Clearance mechanisms of atrial and brain natriuretic peptides in rats. Pharm Res 1994; 11:60–64.PubMedCrossRefGoogle Scholar
  69. 69.
    Perrella MA, Aarhus LL, Heublein DM, Lewicki JA, Burnett J Jr. Biologic role of atrial natriuretic factor clearance receptor in congestive heart failure. Am J Physiol 1993;265:H401–408.PubMedGoogle Scholar
  70. 70.
    Nussenzveig DR, Lewicki JA, Maack T. Cellular mechanisms of the clearance function of type C receptors of atrial natriuretic factor. J Biol Chem 1990;265:20,952–20,958.Google Scholar
  71. 71.
    Johnson GR, Arik L, Pitts BJ, Foster CJ. Rapid receptor-mediated catabolism of 1251–atrial natriuretic factor by vascular endothelial cells. Biochem J 1990;268:771–776.PubMedGoogle Scholar
  72. 72.
    Murthy KK, Thibault G, Cantin M. Binding and intracellular degradation of atrial natriuretic factor by cultured vascular smooth muscle cells. Mol Cell Endocrinol 1989;67:195–206.PubMedCrossRefGoogle Scholar
  73. 73.
    Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 1990;24:133–170.PubMedCrossRefGoogle Scholar
  74. 74.
    Bridges K, Harford J, Ashwell G, Klausner RD. Fate of receptor and ligand during endocytosis of asialoglycoproteins by isolated hepatocytes. Proc Natl Acad Sci USA 1982;79:350–354.PubMedCrossRefGoogle Scholar
  75. 75.
    Fuhrer C, Geffen I, Spiess M. Endocytosis of the ASGP receptor H1 is reduced by mutation of tyrosine-5 but still occurs via coated pits. J Cell Biol 1991;114:423–431.PubMedCrossRefGoogle Scholar
  76. 76.
    Anand-Srivastava MB, Sairam MR, Cantin M. Ring-deleted analogs of atrial natriuretic factor inhibit adenylate cyclase/cAMP system. Possible coupling of clearance atrial natriuretic factor receptors to adenylate cyclase/cAMP signal transduction system. J Biol Chem 1990;265:8566–8572.PubMedGoogle Scholar
  77. 77.
    Anand-Srivastava MB, Gutkowska J, Cantin M. The presence of atrial-natriuretic-factor receptors of ANF-R2 subtype in rat platelets. Coupling to adenylate cyclase/cyclic AMP signal-transduction system. Biochem J 1991;278:211–217.PubMedGoogle Scholar
  78. 78.
    Drewett JG, Ziegler RJ, Trachte GJ. Neuromodulatory effects of atrial natriuretic peptides correlate with an inhibition of adenylate cyclase but not an activation of guanylate cyclase. J Pharmacol Exp Ther 1992;260:689–696.PubMedGoogle Scholar
  79. 79.
    Anand-Srivastava MB, Sehl PD, Lowe DA. Cytoplasmic domain of natriuretic peptide receptor-C inhibits adenylyl cyclase: involvement of a pertussis toxin-sensitive G protein. J Biol Chem 1996;271:19,324–19,329.Google Scholar
  80. 80.
    Hirata M, Chang CH, Murad F. Stimulatory effects of atrial natriuretic factor on phosphoinositide hydrolysis in cultured bovine aortic smooth muscle cells. Biochem Biophys Acta 1989; 1010:346–351.PubMedCrossRefGoogle Scholar
  81. 81.
    Berl T, Mansour J, Teitelbaum I. ANP stimulates phospholipase C in cultured RIMCT cells: roles of protein kinases and G protein. Am J Physiol 1991;260:F590–595.PubMedGoogle Scholar
  82. 82.
    Levin ER, Frank HJ. Natriuretic peptides inhibit rat astroglial proliferation: mediation by C receptor. Am J Physiol 1991;261:R453–457.PubMedGoogle Scholar
  83. 83.
    Cahill PA, Hassid A. Clearance receptor-binding atrial natriuretic peptides inhibit mitogenesis and proliferation of rat aortic smooth muscle cells. Biochem Biophys Res Commun 1991;179:1606–1613.PubMedCrossRefGoogle Scholar
  84. 84.
    Cahill PA, Hassid A. ANF-C-receptor-mediated inhibition of aortic smooth muscle cell proliferation and thymidine kinase activity. Am J Physiol 1994;266:R194–203.PubMedGoogle Scholar
  85. 85.
    Porter JG, Catalano R, McEnroe G, Lewicki JA, Protter AA. C-type natriuretic peptide inhibits growth factor-dependent DNA synthesis in smooth muscle cells. Am J Physiol 1992;263:C1001–1006.PubMedGoogle Scholar
  86. 86.
    Johnson BG, Trachte GJ, Drewett JG. Neuromodulatory effect of the atrial natriuretic factor clearance receptor binding peptide, cANF(4–23)-NH2 in rabbit isolated vasa deferentia. J Pharmacol Exp Ther 1991;257:720–726.PubMedGoogle Scholar
  87. 87.
    Hu RM, Levin ER, Pedram A, Frank HJ. Atrial natriuretic peptide inhibits the production and secretion of endothelin from cultured endothelial cells. Mediation through the C receptor. J Biol Chem 1992;267:17,384–17,389.Google Scholar
  88. 88.
    Kishi Y, Ashikaga T, Watanabe R, Humano F. Atrial natriuretic peptide reduces cyclic AMP by activating cyclic GMP-stimulated phosphodiesterase in vascular endothelial cells. J Cardiovasc Pharmacol 1994;24:351–357.PubMedCrossRefGoogle Scholar
  89. 89.
    MacFarland RT, Zelus BD, Beavo JA. High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells. J Biol Chem 1991;266:136–142.PubMedGoogle Scholar
  90. 90.
    Whalin ME, Scammell JG, Strada SJ, Thompson WJ. Phosphodiesterase II, the cGMP-activatable cyclic nucleotide phosphodiesterase, regulates cyclic AMP metabolism in PC 12 cells. Mol Pharmacol 1991;39:711–717.PubMedGoogle Scholar
  91. 91.
    Kishimoto I, Dubois SK, Garbers DL. The heart communicates with the kidney exclusively through the guanylyl cyclase-A receptor: acute handling of sodium and water in response to volume expansion. Proc Natl Acad Sci USA 1996;93:6215–6219.PubMedCrossRefGoogle Scholar
  92. 92.
    Sano T, Morishita Y, Yamada K, Matsuda Y. Effects of HS-142–1, a novel non-peptide ANP antagonist, on diuresis and natriuresis induced by acute volume expansion in anesthetized rats. Biochem Biophys Res Commun 1992;182:824–829.PubMedCrossRefGoogle Scholar
  93. 93.
    Morishita Y, Sano T, Kase H, Yamada K, Inagami T, Matsuda Y. HS-142–1, a novel nonpeptide atrial natriuretic peptide (ANP) antagonist, blocks ANP-induced renal responses through a specific interaction with guanylyl cyclase-linked receptors. Eur J Pharmacol 1992;225:203–207.PubMedCrossRefGoogle Scholar
  94. 94.
    Gregory LC, Scarborough RM, Metzler CH, McEnroe GA, Maack T, Lewicki JA. Effects of acute infusion of a C-ANP receptor specific compound in conscious dogs. J Cell Biochem Suppl 1988; 12 A:23.Google Scholar

Copyright information

© Humana Press Inc. 1997

Authors and Affiliations

  • John A. Lewicki
  • Andrew A. Protter

There are no affiliations available

Personalised recommendations